Study to Show Lot-to-lot Consistency of Hib-MenAC Mixed With Tritanrix™-HBV, Its Non-inferiority to Tritanrix™-HBV/Hiberix™ With or Without Meningitec™, and MenA Response in 2, 4, 6 Month Infants With Hepatitis B Birth Dose

Trial Profile

Study to Show Lot-to-lot Consistency of Hib-MenAC Mixed With Tritanrix™-HBV, Its Non-inferiority to Tritanrix™-HBV/Hiberix™ With or Without Meningitec™, and MenA Response in 2, 4, 6 Month Infants With Hepatitis B Birth Dose

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2016

At a glance

  • Drugs Hib-meningococcal vaccine groups A and C conjugate (Primary) ; DTP-hepatitis B vaccine; Hib-DTP hepatitis B vaccine (Tritanrix-HepB/Hiberix); Meningococcal vaccine group C conjugate
  • Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal infections; Neisseria infections; Pertussis; Tetanus
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 31 Mar 2011 Added actual start and end dates, as reported by Clinicaltrials.gov.
    • 15 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top